Read more on vaccines and drugs made in Africa:
Patents can take 20 years to expire and one measure to improve local manufacturing in the interim are so-called fill-and-finish agreements. These final steps of production, if done by a number of companies across the continent, can create many thousands of jobs for African pharmacists, biologists and innovators, he said. Aspen, which has 23 manufacturing plants, is gearing up its sterile facility to fill more vials in the southern South African city of Gqeberha.
More African governments are becoming engaged in ensuring there is uptake of what is produced locally, Nicolaou said. Also, international vaccine alliance Gavi will launch its African manufacturing accelerator for doses on June 20. This is designed to support the sustainable growth of Africa’s production base by making make as much as $1 billion available over the next 10 years.
“There is a risk of merely relying on Gavi, which may buy from Asia or wherever is cheaper,” he said. “But when it comes to vaccines at least, we are fairly confident we are able to compete on price, and with the Gavi top-up incentive, can track the Gavi market on the African continent.”
This article is more than a year old
Business Maverick
Africa’s Biggest Drugmaker Sees Move to Vaccine Autonomy
Africa’s plans to increase vaccine autonomy are gaining traction as the continent seeks to reduce its dependence on foreign companies that supply about 80% of the drugs and 99% of the vaccines used in the region, according to Aspen Pharmacare Holdings Ltd.
Comments
Scroll down to load comments...